Search This Blog

Friday, October 23, 2026

Genmab positive Phase 3 data for platinum-resistant ovarian cancer drug, potential rival to Corcept

 

Genmab announces positive Phase 3 data for platinum-resistant ovarian cancer drug, a potential rival to Corcept’s Lifyorli

  • Investing.com highlighted Genmab's Phase 3 success as potential competition for Corcept’s recently approved Lifyorli.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)